₹🎙️
RUPIE SPEAK
🔮 Voice of the Market
✦ NO NOISE · ONLY WISDOM ✦
⚡ SEBI action🏦 RBI booster💊 USFDA approvals📦 mega orders
1) Rajesh Exports shares plunge 5 pc, hit lower circuit for second straight day
🎙️ RUPIE SPEAK
SEBI's interim order is devastating — it alleges that 99.8% of subsidiary revenues (₹15 lakh crore!) were misrepresented. The promoter has been barred from dealing in securities. For retail investors, this is a clear signal: avoid until clarity emerges. Even a denial from the company cannot erase the scale of regulatory allegations.
2) RBI hikes equity investment limits for NRIs, OCIs
🎙️ RUPIE SPEAK
RBI is pulling out all stops to attract foreign capital. NRIs, OCIs, and all PROIs can now invest more freely in Indian equities without SEBI registration. Plus, concessional forex swaps for PSUs, FCNR(B) deposit incentives, and removal of concentration limits on FPI bond investments. This is a clear message: India wants dollars, and it's making it easier for foreign money to come in.
3) Lupin soars on getting USFDA approval for Ranluspec (ranibizumab) injection
🎙️ RUPIE SPEAK
Ranluspec is the only interchangeable biosimilar for ranibizumab approved in the US — in both vial and pre-filled syringe formats. This is a big deal. Biosimilars are high-margin, hard-to-replicate products. Lupin now has a first-mover advantage in a multi-indication drug (wet AMD, diabetic retinopathy, etc.).
4) DMR Engineering jumps on securing Rs 2.58 crore work order
🎙️ RUPIE SPEAK
A ₹2.58 crore order for a micro-cap is small but significant. The client is Dorjilung Hydro Power in Bhutan — a 1125 MW project. Being selected for "owner's engineer services" means trust and technical credibility. Bhutan's hydropower boom is real. This could lead to larger contracts.
5) Glenmark Pharmaceuticals inches up as its arm launches Lacosamide Injection
🎙️ RUPIE SPEAK
US launch of Lacosamide Injection (generic Vimpat) — a $15.2 million market. Not huge, but every launch adds to the US generic portfolio. Glenmark is steadily building its injectables pipeline. The real story is the cumulative effect of many such approvals.
6) Aurobindo Pharma gains on getting USFDA's final nod for Tofacitinib Tablets
🎙️ RUPIE SPEAK
Tofacitinib (generic Xeljanz) has a $494 million US market. Aurobindo has final approval and will launch immediately. This is a significant revenue contributor. With 586 ANDA approvals, Aurobindo remains a US generic powerhouse. Margins on complex drugs like this are attractive.
7) Bharat Gears rises on investing Rs 1.27 crore in equity shares of Hexa Energy HR5
🎙️ RUPIE SPEAK
This investment is not about returns — it's about compliance. Bharat Gears is buying solar power for its Faridabad and Mumbra units. By investing in Hexa Energy, they are fulfilling electricity laws for captive solar consumption. Smart ESG move. Not a profit driver, but cost control.
8) HCC gains after bagging contract worth Rs 127 crore
🎙️ RUPIE SPEAK
Bhutan's Wangchhu Hydroelectric Project — HCC has been in Bhutan for three decades (Tala, Punatsangchhu, etc.). This ₹127 crore contract for diversion tunnels is small but strategic. It keeps them in the game for larger Bhutan hydro projects. Recurring international revenue is a plus.
9) Dhampur Bio Organics soars on signing JV agreement with Orgonew
🎙️ RUPIE SPEAK
Dhampur (sugar/bio-organics) is diversifying into phyto bio-active functional foods. 74% controlling stake in the JV. This is a pivot from commoditised sugar to high-value nutraceuticals. If executed well, margins could see a significant uplift.
10) Nephrocare Health jumps as its arm inks asset transfer pact with Inocentes Dialysis Clinic
🎙️ RUPIE SPEAK
Nephrocare is expanding in the Philippines — acquiring a dialysis center in Quezon City for 30 million pesos. International expansion in healthcare services is capital-light but brand-heavy. Dialysis is recurring, high-margin revenue. Smart adjacent market entry.
11) Venus Remedies touches roof on securing renewal of DSIR R&D recognition for VMRC
🎙️ RUPIE SPEAK
DSIR recognition is not revenue — but it's credibility. Venus's R&D unit VMRC works on antimicrobial resistance (VRP-034, a novel polymyxin formulation with USFDA QIDP status). Renewal means continued tax benefits and validation. The real value lies in pipeline progress.
12) Innovision zooms on bagging toll collection & facility maintenance contract worth Rs 26 crore
🎙️ RUPIE SPEAK
NHAI toll collection contract — one-year, ₹26 crore. This is steady, predictable revenue. Innovision is a small-cap but securing government contracts adds stability. Toll collection is low-risk, high-cash-flow business.
13) ACME Solar Holdings gains on raising Rs 2,800 crore equity capital via QIP
🎙️ RUPIE SPEAK
ACME's first QIP since listing — ₹2,800 crore from marquee investors (BlackRock, ADIA, Goldman Sachs, SBI MF, etc.). Strong demand reflects confidence in India's renewable story. Proceeds will reduce leverage. Balance sheet strength matters for long-term infrastructure players.
14) Government takes slew of measures to attract stable long-term foreign capital flows
🎙️ RUPIE SPEAK
PROIs can now invest up to 24% in a company (up from 10%). FAR route expanded to 15, 30, 40-year G-secs. Concentration and security-wise limits for FPIs removed. Tax exemptions on interest and capital gains for foreign investors. This is a coordinated push to defend the rupee and attract patient capital. Markets will eventually price this in.
15) Alembic Pharmaceuticals rises on getting USFDA's final approval for Haloperidol tablets
🎙️ RUPIE SPEAK
Haloperidol is a mature generic — $27 million US market. Not a blockbuster, but Alembic now has 240 ANDA approvals. Every approval adds to the base. The cumulative effect of a wide portfolio is steady US revenue.
16) BHEL trades higher on bagging NoA worth over Rs 21,000 crore from MUNPL
🎙️ RUPIE SPEAK
₹21,000 crore order for 3x800 MW supercritical thermal plant. Execution over 70 months (~6 years). BHEL's order book now stands at ~₹2.4 lakh crore. Thermal power is not dead — India still needs base load. This order solidifies BHEL's position for years.
17) Tata Technologies trades higher on the BSE
🎙️ RUPIE SPEAK
InnoVent-27 hackathon with Emerson and AWS — theme "AI at the Edge" for automotive, aerospace, industrial machinery. This is talent pipeline building, not immediate revenue. But for an engineering services company, access to top engineering talent is the ultimate moat.
18) BHEL shares jump over 2 pc on bagging Rs 21,000 crore power project order
🎙️ RUPIE SPEAK
This is the same order as #16, but with additional context: BHEL also secured a ₹2,000-2,500 crore order from Nigeria's Dangote Refinery for 8 gas turbine packages. International diversification is a plus. BHEL's Q4 net profit rose 155% YoY. Turnaround story is gaining credibility.
19) Maruti Suzuki India inches up on launching India's first flex-fuel car
🎙️ RUPIE SPEAK
Maruti's Wagon R flex-fuel — runs on E20 to E100. Hero launched flex-fuel bikes yesterday, Maruti launches cars today. The message is clear: India is moving toward ethanol blending aggressively. Maruti's first-mover advantage in flex-fuel cars could be significant if ethanol infrastructure expands.
20) Piccadily Agro Industries rises on launching Indri Ilika
🎙️ RUPIE SPEAK
Indri Ilika — travel retail exclusive single malt at ~$80. Indian single malts are gaining global recognition. Travel retail (airports) is high-margin, high-visibility. This is brand building, not volume play. But if successful, it opens international distribution channels.
21) Asian Energy gains as it empanelled by Oil India for seismic data acquisition services
🎙️ RUPIE SPEAK
Three-year empanelment by Oil India for 2D/3D seismic data acquisition. Similar to South West Pinnacle's news yesterday. Empanelment doesn't guarantee orders, but it's a necessary first step. Seismic services are technical, high-entry-barrier. This validates their expertise.
22) Bajaj Housing Finance surges on raising Rs 1,991.83 crore via NCDs
🎙️ RUPIE SPEAK
₹1,992 crore via NCDs on private placement. Bajaj Housing Finance is scaling up. Housing finance is a capital-intensive business. Raising debt at reasonable rates is critical. This gives them ammunition to grow the loan book.
23) Bluspring Enterprises jumps as its arm secures contract worth Rs 2,049 crore
🎙️ RUPIE SPEAK
5-year O&M contract for 1740 MW power plant from Bharat Aluminium Company (Balco). ₹2,049 crore over 60 months = ~₹410 crore annual recurring revenue. This is the kind of annuity business that creates long-term value. STEAG Energy Services (India) is a serious O&M player.
24) ACME Solar successfully completes INR 2,800 Crore Qualified Institutional Placement
🎙️ RUPIE SPEAK
Marquee investor participation (BlackRock, ADIA, Goldman Sachs, SBI MF) signals strong confidence in renewable energy and ACME's execution. Proceeds to reduce leverage — a sign of prudent capital management.
25) Monarch Surveyors zooms on securing LoA worth Rs 2.16 crore from Maharashtra Maritime Board
🎙️ RUPIE SPEAK
DPR preparation for New Marine Shipyard Cluster at Dighi, Raigad. ₹2.16 crore is small, but shipyard DPRs can lead to larger project management contracts. Monarch is a micro-cap. Every government order adds credibility.
26) Government exempts foreign investors from tax on interest, capital gains on G-Secs
🎙️ RUPIE SPEAK
Ordinance exempting FPIs from tax on G-sec interest and capital gains, effective April 1, 2026. Withdrawal of withholding tax (20%) and LTCG/STCG exemptions. This is a big structural reform. India is saying: "Come, invest in our bonds, keep your returns." This should attract pension funds, sovereign wealth funds, and long-only bond investors over time.
⚠️ SEBI REGULATORY DISCLAIMER — EDUCATIONAL & INFORMATIONAL ONLY
The above views are of the author and not of the website. This report is for informational and educational purposes only and does NOT constitute investment advice, a research report, or a solicitation to buy/sell securities. The author/publisher is NOT a SEBI-registered Research Analyst.
Stock markets carry risk. Past performance is not indicative of future results. Readers are strongly advised to consult a SEBI-registered investment adviser before making any financial decisions.
📞 SEBI SCORES Helpline: 1800 266 7575 | sebi.gov.in
The above views are of the author and not of the website. This report is for informational and educational purposes only and does NOT constitute investment advice, a research report, or a solicitation to buy/sell securities. The author/publisher is NOT a SEBI-registered Research Analyst.
Stock markets carry risk. Past performance is not indicative of future results. Readers are strongly advised to consult a SEBI-registered investment adviser before making any financial decisions.
📞 SEBI SCORES Helpline: 1800 266 7575 | sebi.gov.in